

State of Oklahoma Brukinsa[®] (Zanubrutinib) Prior Authorization Form

Member Name:	Date of Birt	h: Member ID#:	
	Drug Info		
Pharmacy billing (NDC:		art Date (or date of next dose):	
		· · · · · · · · · · · · · · · · · · ·	
	Billing Provide	r Information	
Pharmacy NPI:	Pharmacy Name:		
Pharmacy Phone:	Pharmacy Fax:		
Prescriber Information			
Prescriber NPI: Prescriber Name:		Name:	
Prescriber Phone:	Prescriber Fax:	Specialty:	
Criteria			
For Initial Authorization:			
 Please indicate the diagnosis and information: Mantle Cell Lymphoma (MCL) 			
A. Has member received at least 1 prior therapy? Yes No			
Marginal Zone Lymphoma (MZL)			
A. Has member received at least 1 prior anti-CD20 monoclonal antibody-based therapy?			
YesNo			
Waldenström's Macroglobulinemia			
A. Will Brukinsa [®] be used as primary therapy? Yes No B. Will Brukinsa [®] be used as subsequent treatment? Yes No			
 Official de used as subsequent realment? resNo Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) 			
 Chronic Lymphocytic Leukema/smail Lymphocytic Lymphoma (CLL/SLL) Follicular Lymphoma (FL) 			
A. Will Brukinsa [®] be used as third line or subsequent therapy for no response, relapsed, or progressive			
disease? YesNo			
B. Will Brukinsa [®] be used in combination with obinutuzumab? Yes No			
□ If diagnosis is not listed above, please indicate diagnosis:			
Additional Information:			
For Continued Authorization:			
1. Date of last dose:			
2. Does member have any evidence of progressive disease while on zanubrutinib? Yes No			
3. Has the member experienced any adverse drug reactions related to zanubrutinib therapy? Yes No			
If yes, please specify adverse reactions:			
Prescriber Signature: Date:			
I certify that the indicated treatment is n knowledge. Failure to complete this form i		and all information is true and correct to the best of my cessing delays.	
PLEASE PROVIDE THE INFORMATION REQUES	TED AND RETURN TO:	CONFIDENTIALITY NOTICE	
University of Oklahoma College of Pharmacy Management Const		This document, including any attachments, contains information which is	
Product Based Prior Authorizat		confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this	
Fax: 1-800-224-4014		information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return	
Phone: 1-800-522-0114 Opt	tion 4	of the transmitted documents or to verify their destruction.	